Also known as: venous thromboembolic events, VTE
Venous thromboembolism encompasses deep vein thrombosis and pulmonary embolism, caused by abnormal clot formation in venous circulation. It is a major source of preventable morbidity and mortality.
A study finds end-to-side anastomosis for Crohn’s disease may reduce endoscopic recurrence, while global data show early-onset colorectal cancer has the highest GI cancer burden in young adults, with rising incidence. Both studies highlight evolving challenges and treatment options in gastroenterology.
Hematologic cancer survivors face elevated CVD risk and fourfold higher heart failure risk. Cardiac screening is low among cardiotoxic treatment recipients. A trial found simple risk assessment may suffice.
Two phase 3 trials found upadacitinib 15 mg significantly improved facial and total repigmentation versus placebo at 48 weeks in nonsegmental vitiligo. The 614-patient studies also showed continued improvement over time and a safety profile consistent with prior use.
A study identified host-response plasma protein candidate biomarkers to predict venous thromboembolism risk after pleural mesothelioma surgery. The exploratory cohort included 18 patients.
A clinical study in Shock found that Nu.Q H3.1 and H3R8 Citrulline were significantly elevated in 674 trauma patients, especially those who developed VTE. The findings point to potential clinical utility for trauma care and support commercialization of Nu.Q NETs.
CRISPR Therapeutics reported a Q4 2025 loss of $1.37 per share, missing estimates, with revenues of $0.9 million falling short of expectations. The company's partner Vertex recorded $54 million in Casgevy sales for the quarter, with regulatory submissions for pediatric label expansion planned for early 2026.
The FDA has approved a once-monthly dosing schedule for subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) combined with lazertinib for first-line treatment of EGFR-mutated advanced NSCLC, based on PALOMA-2 trial data showing comparable efficacy to biweekly dosing.
The FDA approved a once-monthly dosing schedule for Rybrevant Faspro with Lazcluze for first-line treatment of EGFR-mutated advanced NSCLC, reducing clinic visits while maintaining safety and efficacy established with bi-weekly dosing.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07767279 |
High-Risk Factors for VTE Death |
COMPLETED | |
| NCT07702903 |
The Effect of a VTE Prevention Care Bundle in Total Hip Arthroplasty Patients |
ACTIVE_NOT_RECRUITING | NA |
| NCT07689136 |
Timing of Thromboprophylaxis After Postpartum Hemorrhage |
COMPLETED | |
| NCT07612865 |
People's Hospital of Xinjiang Uygur Autonomous Region |
COMPLETED | NA |
| NCT07603700 |
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism |
NOT_YET_RECRUITING | |
| NCT07596264 |
Development and Validation of an Interpretable Machine Learning Model for Predicting Venous Thromboembolism（VTE）in Intensive Care Unit (ICU) Patients |
COMPLETED | |
| NCT07506473 |
Intermediate Versus Standard Dose Enoxaparin to Prevent Venous Thromboembolism in Severe Trauma Patients: a Multicenter Double Blind Randomised Controlled Trial |
NOT_YET_RECRUITING | NA |
| NCT07499661 |
Pulmonary Embolism in Patients With Acute Heart Failure (PEHF Study) |
RECRUITING | NA |
| NCT07399977 |
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism |
RECRUITING | NA |
| NCT07350499 |
Aspiration Thrombectomy Using the Symphony or Prodigy System |
RECRUITING |
